טוען...
The anti-tumor effects of entinostat in ovarian cancer require adaptive immunity
BACKGROUND: Ovarian cancer is poorly immunogenic; however, increased major histocompatibility complex class II (MHCII) expression correlates with improved immune response and prolonged survival in ovarian cancer patients. We previously demonstrated that the histone deacetylase inhibitor entinostat i...
שמור ב:
| הוצא לאור ב: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6294677/ https://ncbi.nlm.nih.gov/pubmed/30423192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31761 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|